| アブストラクト | Objective: To understand the impact of von Willebrand disease (VWD) on women's health, a retrospective cohort study was conducted using UK Clinical Practice Research Datalink (CPRD) GOLD database and Hospital Episode Statistics (HES) Admitted Patient Care data from 1988 to 2016. Materials and Methods: Hysterectomy and heavy menstrual bleeding (HMB) events were identified by recorded disease/clinical codes and compared in women with and without VWD (matched 1:10 by birth and CPRD record start years [+/-2 years], and general practice attended). Incidence rates and incidence rate ratios (IRR) were calculated; risks were estimated using the Kaplan-Meier method. Results: HMB was recorded after cohort entry in 388 of 1,335 women (29.1%) with VWD and 1,524 of 12,463 women (12.2%) without VWD. The cumulative incidence of HMB was higher in women with versus without VWD across all ages (p < 0.0001), and irrespective of prior HMB status (p < 0.001). Women with VWD were more likely to have HMB compared with women without VWD; IRR adjusted for age and prior HMB status was 2.74 (95% confidence interval [CI]: 2.44-3.07). Hysterectomy was recorded in 88 of 1,374 women (6.4%) with VWD and 320 of 12,791 women (2.5%) without VWD. The cumulative incidence of hysterectomy was higher for women with versus without VWD (p < 0.0001), and highest among women aged >/=30 years at cohort entry. Women with VWD aged 30 - 39 years were more likely to undergo hysterectomy than women without VWD; IRR adjusted for prior HMB was 3.58 (95% CI: 2.36 - 5.44). Conclusions: These findings highlight the substantial impact of VWD on women's health. |
|---|
| ジャーナル名 | Journal of women's health (2002) |
|---|
| Pubmed追加日 | 2022/8/13 |
|---|
| 投稿者 | Hagberg, Katrina Wilcox; Jick, Susan; Du, Ping; Truong Berthoz, Francoise; Ozen, Gulden; Tzivelekis, Spiros |
|---|
| 組織名 | Boston Collaborative Drug Surveillance Program, Lexington, Massachusetts, USA.;Boston University School of Public Health, Boston, Massachusetts, USA.;Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.;Takeda Pharmaceuticals International AG, Zurich, Switzerland. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35960825/ |
|---|
